Square Pharmaceuticals Ltd clocked a Tk 1,491.01 crore profit in the July-March period of the ongoing financial year, up 4.9 per cent from a year earlier.

The pharmaceuticals giant made a profit of Tk 1,420.98 crore during the identical nine-month period a year earlier.

Thus, its consolidated earnings per share were Tk 16.82 for July-March of 2022-23 compared to Tk 16.03 in the same period of 2021-22.

Square Pharmaceuticals' profit, however, was down 6.20 per cent to Tk 428.16 crore in the third quarter of FY23. It was Tk 456.52 crore in the same quarter of FY22.

The consolidated EPS stood at Tk 4.83 in January-March against Tk 5.15 in the same quarter a year ago, according to the unaudited financial statements.

The consolidated net operating cash flow per share slipped to Tk 10.95 in July-March from Tk 13.87 a year ago.

The NOCFPS decreased due to the ongoing complexity in the procurement of raw materials and protracted lead time, said the company in a filing on the Dhaka Stock Exchange today.

The Group has paid its regular suppliers in advance to ensure that the supply chain does not face any disruption, it said.